Caribou Biosciences
CRBU
120 hedge funds and large institutions have $185M invested in Caribou Biosciences in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 43 increasing their positions, 28 reducing their positions, and 24 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 28
5% more call options, than puts
Call options by funds: $111K | Put options by funds: $106K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.09% less ownership
Funds ownership: 73.39% → 71.3% (-2.1%)
5% less funds holding
Funds holding: 126 → 120 (-6)
22% less capital invested
Capital invested by funds: $238M → $185M (-$52.8M)
25% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$2.51M |
| 2 |
Walleye Capital
New York
|
+$2.22M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.81M |
| 4 |
Millennium Management
New York
|
+$1.79M |
| 5 |
Alkeon Capital Management
New York
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$10.3M |
| 2 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$2.43M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.26M |
| 4 |
Rafferty Asset Management
New York
|
-$1.24M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$1.15M |
CRBU Hedge Fund Activity: Q2 2023 in Review
120 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q2 2023, worth a combined $185M — down 22% from $238M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CRBU and 18 opened new positions — a net loss of 6 holders — while 28 trimmed existing stakes and 43 added.
The largest buyer was PFM Health Sciences, adding an estimated $2.51M. The largest seller was State Street, cutting an estimated $10.3M.
- 120 institutional investors held Caribou Biosciences (CRBU) as of Q2 2023, down from 126 in Q1 2023.
- Funds reported $185M of Caribou Biosciences stock for Q2 2023, down 22% quarter-over-quarter.
- 18 funds opened new Caribou Biosciences positions in Q2 2023 and 24 closed out, a net change of -6 holders.
- The largest Caribou Biosciences buyer in Q2 2023 was PFM Health Sciences, an estimated $2.51M added.
- The largest Caribou Biosciences seller in Q2 2023 was State Street, an estimated $10.3M sold.
Based on aggregated 13F filings for Q2 2023.